tbuckley/cabot-search huggingface dataset:
Statins, news, and nuance
Authors: Gary Schwitzer
Journal: BMJ (2016)

Journalism that exposes the public to ongoing controversies in science should be nurtured

Did news coverage of questions about the risk:benefit balance of statins influence their use in the United Kingdom? In a linked paper, Matthews and colleagues (doi:10.1136/bmj.i3283) assert that it did, describing “impact,” “the effect of negative media coverage,” and “a transient rise in the proportion of people who stopped taking statins.”1 They assumed causality but did not prove it, despite the causal language used.

The news in question was not all negative. Stories swung between extremes. One newspaper headline claimed that “statins do not have major side effects” just days after another newspaper headlined “millions face terrible side effects as [statin] prescription escalates.” Those two stories might have had very different effects on current or potential statin users.

Two stories are a slim sample on which to base conclusions, but that is all the authors cited, after describing “widespread media coverage” over a six month period that was both “intense” and “negative.” In one story, less than 20% of the text …
Primary Prevention of Sexual Dysfunction With Mediterranean Diet in Type 2 Diabetes: The MÈDITA Randomized Trial
Authors: Maria Ida Maiorino, Giuseppe Bellastella, Paolo Chiodini, Ornella Romano, Lorenzo Scappaticcio, Dario Giugliano, Katherine Esposito
Journal: Diabetes Care (2016)

Type 2 diabetes has been associated with sexual dysfunction in men and women (1). Erectile dysfunction (ED) is a marker of significantly increased risk of cardiovascular disease and all-cause mortality in men with diabetes and the general population; however, no data support a clear role for female sexual dysfunction (FSD) as a predictor of future cardiovascular events in women with diabetes.

There is some evidence from clinical trials that sexual dysfunction is amenable to amelioration with interventions based on diet and lifestyle modification in men and women (2). Using the data of the MEditerranean DIet and Type 2 diAbetes (MEDITA) randomized trial (3), we investigated the long-term effect of Mediterranean diet on 1 ) incident ED and FSD in people with type 2 diabetes and 2 ) combined incidence of sexual dysfunction (men or women) with worsening of sexual function in those participants with sexual dysfunction at baseline.

Participants in the two-arm, single-center MEDITA trial were randomly assigned to a Mediterranean diet ( n = 108) or a low-fat …
Influenza vaccination coverage in England, 2000-2008
Authors: R  G Pebody, F Begum, P Gates, K Noakes, D Salisbury
Journal: Eurosurveillance (2008)

For several years, the Health Protection Agency on behalf of Department of Health has undertaken routine annual uptake monitoring of the seasonal influenza vaccination programme in England in order to provide an annual estimate of uptake in targeted groups. In 2007-8, 95% of 8,375 GP practices in England took part in data collection. The national mean uptake in those 65 years and above in England was 74%, approaching the WHO target of 75%.
Blunted aldosterone and ACTH release after human CRH administration in depressed patients
Authors: F Holsboer, A Gerken, G K Stalla, O A Müller
Journal: American Journal of Psychiatry (1987)

The authors measured pituitary adrenocortical responses to human corticotropin-releasing hormone (CRH) in 10 patients with a major depressive episode and 10 matched control subjects. Depressed patients had a significantly lower aldosterone and ACTH release, but cortisol and corticosterone responses were not different between groups.
Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Authors: Jorge E Romaguera, Michelle A. Fanale, Felipe Samaniego, Luis E Fayad, Fredrick B Hagemeister, Peter McLaughlin, Maria Alma Rodriguez, Pam Weaver, Kim Hartig, Maria Badillo, Larry W. Kwak, Anas Younes, Barbara Pro, Michael Wang
Journal: Blood (2013)
Pharmacokinetic and pharmacodynamic study of ramosetron to prevent chemotherapy-induced nausea and vomiting.
Authors: Hyun-Jeong Shim, Sang-Hee Cho, Ik-Joo Chung, Jun-Eul Hwang, Woo Kyun Bae, Gaeun Kang, In-Jae Oh, Sook-In Jung
Journal: Journal of Clinical Oncology (2014)

e20650 Background: Chemotherapy induced nausea and vomiting (CINV) is one of the most concerning adverse effects from cytotoxic chemotherapy. Despite appropriate use of antiemetic guidelines, 20-30 % of patients experience breakthrough nausea and vomiting secondary to chemotherapy. This study was prospectively conducted to determine the optimal concentration of ramosetron to prevent CINV based on pharmacokinetics (PK) and pharmacodynamics (PD) using Rhodes index (RI) as a clinical parameter. Methods: Patients who treated FOLFOX adjuvant chemotherapy after colon cancer surgery were randomized into three groups following as ramosetron 0.3mg (standard dose), 0.45mg and 0.6mg intravenously before chemotherapy. Plasma concentration of ramosetron was measured at 10min, 1hr, 6hrs, 24hrs and 48hrs and patients were evaluated the Rhodes Index of nausea, vomiting and retching (RINVR) to grade CINV at each time. Results: Fifty-one patients were enrolled in this study and one patient decided to refuse, so data from fifty patients were analyzed. The serious AE was not shown according to dose escalation. PK parameters were approximately dose-proportional (Table). In correlation analysis, AUClast is significantly associated with dose escalation (p=0.022) and it trends to reverse correlation to RINVR (p=0.061) according to dose level. When the patients divided into two groups based on median AUClast, patients in higher level of AUClast showed significantly improved RINVR score than lower level of AUClast (p=0.048). Conclusions: Ramosetron showed generally dose-proportional PK parameters and this study suggested that higher dose of ramosetron could be used to improve CINV in subsequent cycle of chemotherapy. Also RINVR is important tool for assessing of CINV to predict optimal antiemetic use, therefore individual approach for managing of CINV is needed. 0.3mg (N=17) 0.45mg (N=15) 0.6mg (N=18) Tmax(h) 0.17 0.17 0.17 Cmax(ng/ml) 3.2±0.98 4.9±2.19 7.3±4.43 AUClast(ng.h/ml) 16.5±5.1 23.0±8.95 28.1±10.23
Childhood Trauma as a Neglected Factor in Psychotic Experiences and Cognitive Functioning—Reply
Authors: Josephine Mollon, Craig Morgan, Abraham Reichenberg
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Case 37-1980
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Arnold H. Colodny, David L. Gang
Journal: New England Journal of Medicine (1980)

Presentation of CaseA 10-year-old boy was admitted to the hospital because of an abdominal mass.He was well until six weeks previously, when he began to complain of intermittent abdominal pain. Four weeks before admission the pain became more severe, and he was taken to another hospital, where an appendectomy was performed; no mass was observed on exploration of the abdomen. Microscopical examination of the excised specimen showed focal periappendicitis. He was sent home on the fourth postoperative day. He felt well subsequently until 10 days before entry, when he gradually became listless, with general malaise. A physician found . . .
Current advances in orthodontic pain
Authors: Hu Long, Yan Wang, Fan Jian, Li-Na Liao, Xin Yang, Wen-Li Lai
Journal: International Journal of Oral Science (2016)

Orthodontic pain is an inflammatory pain that is initiated by orthodontic force-induced vascular occlusion followed by a cascade of inflammatory responses, including vascular changes, the recruitment of inflammatory and immune cells, and the release of neurogenic and pro-inflammatory mediators. Ultimately, endogenous analgesic mechanisms check the inflammatory response and the sensation of pain subsides. The orthodontic pain signal, once received by periodontal sensory endings, reaches the sensory cortex for pain perception through three-order neurons: the trigeminal neuron at the trigeminal ganglia, the trigeminal nucleus caudalis at the medulla oblongata and the ventroposterior nucleus at the thalamus. Many brain areas participate in the emotion, cognition and memory of orthodontic pain, including the insular cortex, amygdala, hippocampus, locus coeruleus and hypothalamus. A built-in analgesic neural pathway—periaqueductal grey and dorsal raphe—has an important role in alleviating orthodontic pain. Currently, several treatment modalities have been applied for the relief of orthodontic pain, including pharmacological, mechanical and behavioural approaches and low-level laser therapy. The effectiveness of nonsteroidal anti-inflammatory drugs for pain relief has been validated, but its effects on tooth movement are controversial. However, more studies are needed to verify the effectiveness of other modalities. Furthermore, gene therapy is a novel, viable and promising modality for alleviating orthodontic pain in the future. Chinese researchers describe the advances in treatment options designed to alleviate the discomfort of orthodontic patients. Orthodontic pain is caused by tooth movement, leading to an immune response and local inflammation. Hu Long and colleagues at the West China Hospital of Stomatology in Chengdu review the current understanding of the etiology of orthodontic pain, and the strategies available to treat the suffering of patients. The cellular products of tissue compression and local inflammation act directly on nerve endings to produce painful sensations. Clinical management of this pain can include medication, laser therapy, cognitive approaches (to alleviate the psychological stress), and, potentially, gene therapy. The authors concede that there is more to understand regarding orthodontic pain; however, the techniques described present promising avenues of exploration for effective therapy.
Idelalisib Bolsters CLL Regimen
Authors: Mitch Leslie
Journal: Cancer Discovery (2016)

Abstract Idelalisib enhances the effectiveness of bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. The addition of idelalisib increased progression-free survival in these patients from 11 months to 23 months, but it also increased the incidence of side effects.
BMA annual meeting: Porter slams EU “leave” campaigners for NHS funding claims
Authors: Abi Rimmer
Journal: BMJ (2016)

The BMA has criticised politicians who are campaigning for the United Kingdom to leave the European Union for making false claims about NHS funding.

Mark Porter, the BMA’s chair of council, condemned the claims in his keynote speech at the BMA’s annual representatives meeting in Belfast on Monday 20 June. Although the BMA’s position on the referendum to leave the EU is neutral, Porter said that the association could not remain neutral in condemning claims that the NHS would receive billions …
Case 18-1966
Authors: Langdon Parsons, Robert E. Scully
Journal: New England Journal of Medicine (1966)

Presentation of CaseA fifty-eight-year-old para 1, gravida 1, woman, eight years postmenopausal, entered the hospital because of vaginal bleeding.She had been well until thirteen months previously, when she first noticed a vaginal discharge that varied from reddish to brown. Vaginal spotting persisted over the next three weeks. Cytologic examination of the vaginal secretions was negative. Pelvic examination under anesthesia at another hospital disclosed occlusion of the external cervical os; the uterus was normal in size, and no masses were felt. Dilatation and curettage were performed, yielding a minimal amount of tissue; microscopical examination revealed blood clot, normal columnar . . .
Three different areas of decreased hepatic radioactivity secondary to a hilar mass.
Authors: SHIRO AKAKI, YOSHIHIRO OKUMURA, KOTARO YASUI, SUSUMU KANAZAWA, IZUMI TOGAMI, YOSHIHIRO TAKEDA
Journal: Clinical Nuclear Medicine (2001)

AKAKI, SHIRO M.D.; OKUMURA, YOSHIHIRO M.D.; YASUI, KOTARO M.D.; KANAZAWA, SUSUMU M.D.; TOGAMI, IZUMI M.D.; TAKEDA, YOSHIHIRO M.D. AND YOSHIO HIRAKI, M.D. Author Information
Analysis Of Micro-RNA-142 Mutations In a Cohort Of 944 Patients With MDS and AML
Authors: Felicitas Thol, Aylin Kirchner, Rabia Shahswar, Sofia Kade, Christian Koenecke, Michael Stadler, Uwe Platzbecker, Christian Thiede, Thomas Schroeder, Guido Kobbe, Gesine Bug, Oliver G. Ottmann, Wolf-Karsten Hofmann, Nicolaus Kröger, Juergen Krauter, Arnold Ganser, Michael Heuser
Journal: Blood (2013)
PD-023 Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
Authors: L.-T. Chen, J. Siveke, A. Wang-Gillam, R. Hubner, S. Pant, T. Dragovich, V. Chung, D. Chang, P. Ross, P. Cooray, N. Tebbutt, F. Franke, B. Belanger, N. Dhindsa, F. de Jong, K. Mamlouk, D. Von Hoff
Journal: Annals of Oncology (2016)
IgE-reactivity profiles to nonspecific lipid transfer proteins in a northwestern European country
Authors: Margaretha A. Faber, Athina L. Van Gasse, Ine I. Decuyper, Astrid Uyttebroek, Vito Sabato, Margo M. Hagendorens, Chris H. Bridts, Luc S. De Clerck, Montserrat Fernandez-Rivas, Mariona Pascal, Araceli Diaz-Perales, Didier G. Ebo
Journal: Journal of Allergy and Clinical Immunology (2016)
An American Text=book of Applied Therapeutics for the Use of Practitioners and Students.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Experimental Carcinogenicity of Coal-Tar Fractions: The Carcinogenicity of Creosote Oils&lt;xref ref-type="author-notes" rid="FN1"&gt;2&lt;/xref&gt;&lt;xref ref-type="author-notes" rid="FN2"&gt;3&lt;/xref&gt;
Authors: William E. Poel, A. G. Kammer
Journal: JNCI Journal of the National Cancer Institute (1957)

Experimental Carcinogenicity of Coal-Tar Fractions: The Carcinogenicity of Creosote Oils Get access William E. Poel, William E. Poel Research Associate Department of Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania Search for other works by this author on: Oxford Academic PubMed Google Scholar A. G. Kammer A. G. Kammer Head Department of Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 18, Issue 1, January 1957, Pages 41–55, https://doi.org/10.1093/jnci/18.1.41 Published: 01 January 1957 Article history Received: 24 July 1956 Published: 01 January 1957
Optimization of Morpholino Antisense Oligonucleotides Targeting the Intronic Repressor Element1 in Spinal Muscular Atrophy
Authors: Erkan Y Osman, Charles W Washington, Kevin A Kaifer, Chiara Mazzasette, Teresa N Patitucci, Kyra M Florea, Madeline E Simon, Chien-Ping Ko, Allison D Ebert, Christian L Lorson
Journal: Molecular Therapy (2016)

Loss of Survival Motor Neuron-1 (SMN1) causes Spinal Muscular Atrophy, a devastating neurodegenerative disease. SMN2 is a nearly identical copy gene; however SMN2 cannot prevent disease development in the absence of SMN1 since the majority of SMN2-derived transcripts are alternatively spliced, encoding a truncated, unstable protein lacking exon 7. Nevertheless, SMN2 retains the ability to produce low levels of functional protein. Previously we have described a splice-switching Morpholino antisense oligonucleotide (ASO) sequence that targets a potent intronic repressor, Element1 (E1), located upstream of SMN2 exon 7. In this study, we have assessed a novel panel of Morpholino ASOs with the goal of optimizing E1 ASO activity. Screening for efficacy in the SMNΔ7 mouse model, a single ASO variant was more active in vivo compared with the original E1(MO)-ASO. Sequence variant eleven (E1(MOv11)) consistently showed greater efficacy by increasing the lifespan of severe Spinal Muscular Atrophy mice after a single intracerebroventricular injection in the central nervous system, exhibited a strong dose-response across an order of magnitude, and demonstrated excellent target engagement by partially reversing the pathogenic SMN2 splicing event. We conclude that Morpholino modified ASOs are effective in modifying SMN2 splicing and have the potential for future Spinal Muscular Atrophy clinical applications.
Coenzyme Q10 as a Peripheral Biomarker for Multiple System Atrophy
Authors: Sheng-Han Kuo, Catarina M. Quinzii
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Reduced Intensity Vs. Standard Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial)
Authors: Nicolaus Kröger, Ronald Brand, Dietger Niederwieser, Uwe Platzbecker, Kai Hübel, Thomas Weber, Marie Robin, Matthias Stelljes, Boris V Afanasiev, Dominik Heim, Giorgio Lambertenghi Deliliers, Francesco Onida, Peter Dreger, Massimo Pini, Stefano Guidi, Liisa Volin, Martin Gramatzki, Wolfgang A. Bethge, Xavier Poire, Guido Kobbe, Marleen van Os, Simona Iacobelli, Theo de Witte
Journal: Blood (2014)
Novel CBF beta-MYH11 fusion transcripts and alternative splicing in acute myeloid leukemia with inversion of chromosome 16 [letter; comment] [see comments]
Authors: M Novak, K Laczika, M Mitterbauer, B Purtscher, A Scheidel-Petrovic, K Lechner, U Jaeger, OA Haas
Journal: Blood (1995)
Evidence for a Common Immune Pathophysiology in Acquired Aplastic Anemia and Ulcerative Colitis
Authors: Noriharu Nakagawa, Hiroyuki Maruyama, Yoshitaka Zaimoku, Kana Maruyama, Chizuru Saito, Takamasa Katagiri, Kohei Hosokawa, Ken Ishiyama, Hirohito Yamazaki, Shinji Nakao
Journal: Blood (2015)
I’m a healthy patient; get me out of here
Authors: John Appleby
Journal: BMJ (2016)

Delays in discharging patients can’t be blamed solely on social care, finds John Appleby 

Ask hospital finance directors what concerns them most at the moment and two issues are increasingly top of their list: problems with getting patients into hospital and problems getting them out.1 The two are not, of course, unconnected. In fact, the measure of problems of getting out of hospital—delayed transfers of care—connects with the whole process of hospital and out-of-hospital care, from the use of beds and clinical decisions to treat, to the flows (and blockages) in emergency departments. Apart from the costs of delays to patients in emotional and health terms, the cost to the NHS has been estimated at £900m (€1000m; $1200m) a year.2 Other estimates put it at around £540m a year.3

The numbers of patients in a hospital bed but ready to be discharged fell between 2007 and 2010, and then stayed relatively …